What changed from existing technology?
This article updates a training program for drug safety monitoring, created by the World Health Organization and a global group of experts. It includes new topics like artificial intelligence and digital health, and was developed with input from many professionals around the world.
The curriculum includes new topics like artificial intelligence and digital health, which were not previously part of standard pharmacovigilance training programs.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 3
l resistance, digital health, artificial intelligence, real-world evidence, medical device safety, the environmental impact of medicines, risk communication and
Abstract ↗ironmental impact of medicines, risk communication and patient engagement are addressed. The curriculum was developed through an international collaboration
Abstract ↗OpenAlex author affiliations: Bayer (Germany), Link Consulting, Alexion Pharma (Switzerland), Sanden (Japan)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This curriculum can be used to train healthcare professionals in modern pharmacovigilance practices, including emerging technologies and global health challenges.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchThe WHO-ISoP Pharmacovigilance Curriculum: 2026 UpdateDrug Safety · Published 2026-09-20 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.